ASCO Annual Meeting

Living in food deserts links to aggressive ctDNA mutations and shorter metastatic breast cancer survival, with the starkest survival gaps seen in Black patients.

Phase 2 study presented at ASCO 2026 shows fedratinib eases symptoms and shrinks spleens in rare MDS/MPN variants, offering a needed evidence-based option.

Allostatic load links chronic stress and social factors to early-onset cancer risk, offering a measurable path to improve risk models and prevention strategies.

Saad Z. Usmani, MD, MBA, shares guidance on improving tolerability of belantamab mafodotin based on clinical experience and findings from in the DREAMM-9 trial.

These 5 noteworthy abstracts provide a deeper dive into the 2026 ASCO gastrointestinal cancers data.

Saad Z. Usmani, MD, MBA, discusses the significance of the final analysis of the phase 3 CEPHEUS trial in newly diagnosed multiple myeloma.

ASCO 2026 data link chronic-stress allostatic load to higher early-onset cancer risk, suggesting new tools for screening beyond genetics.

Dr Tolaney discusses ASCENT-04 data, showing sacituzumab govitecan plus pembrolizumab improves PFS in 1L mTNBC across all Trop-2, tBRCA, and HER2 subgroups.

Michael C. Heinrich, MD, discusses the eventual goal of using velzatinib as an early-line treatment for gastrointestinal stromal tumors.

5 noteworthy abstracts from a deeper dive into the ASCO genitourinary cancers data.

Mabel Mardones, MD, discusses findings from the phase 3 perservERA trial presented at ASCO 2026.

ASCO 2026 insights on 177Lu-PSMA-617 in mHSPC: safety, marrow and kidney monitoring, and what long-term MDS/AML risks may reveal.

Michael C. Heinrich, MD, discusses promising KIT mutation analyses from the phase 1b StrateGIST study in gastrointestinal stromal tumors.

Posttransplant revumenib maintenance in genetically defined AML shows promising survival and low relapse, with thrombocytopenia as key toxicity.

Tucatinib plus trastuzumab/pertuzumab continued to show benefit in patients with HER2+ breast cancer regardless of distinguishing disease features.

"The VIKTORIA-1 trial validates the PAM pathway as a molecular driver in hormone receptor–positive, HER2-negative advanced breast cancer, regardless of PIK3CA mutation status," said Sara Hurvitz, MD.

“The results from this phase 3 study support iza-bren as a new standard of care for patients with pretreated metastatic triple-negative breast cancer,” said Jiong Wu, MD, PhD.

"DISC-0974 treatment resulted in sustained hepcidin and serum iron, regardless of concomitant JAKi therapy or baseline transfusion requirement,” said Naseema Gangat, MBBS.

Meredith McKean, MD, discusses promising results from a trial of imneskibart with low-dose IL-2 and nivolumab in advanced melanoma.

Long-term INDIGO data show vorasidenib extends progression-free survival, delays next treatment, and cuts seizures in post-surgery IDH-mutant glioma.

"Sacituzumab govitecan plus pembrolizumab [led to] improvement in PFS2...despite the crossover design of the trial," said Eleonora Teplinsky, MD.

A review of top ASCO abstracts with the potential to change everyday oncology practice.

ASCO 2026: PSMAddition shows 177Lu-PSMA-617 boosts rPFS across mHSPC subgroups, with steady safety and insights on PSMA PET selection.

Andrew L. Pecora, MD, discusses the significance of the long-term findings from the KEYNOTE-942 trial of intismeran autogene and how it enhances the immune response.

"This is one of very few studies in advanced squamous NSCLC that has shown median survival beyond 2 years," said Shun Lu, MD, PhD.

A PD-1/TIGIT bispecific antibody plus T-DXd yielded pathologic complete responses, avoiding need for further chemotherapy.

Dr Pant highlights phase 3 data showing oral daraxonrasib nearly doubles overall survival vs chemotherapy in metastatic pancreatic cancer.

Five-year KEYNOTE-942 data show intismeran plus pembrolizumab delivers durable improvements in RFS and DMFS in high-risk resected melanoma.

“In this interim analysis…the response rate with the zelenectide pevedotin and pembrolizumab [was] promising, supporting its benefit-risk profile and supporting…the optimized dosing," said Yohann Loriot, MD, PhD.

Dr McDonald shares promising data linking GLP-1 use to lower breast cancer risk, highlighting the need for clinical trials to prove prevention.